Adam Walsh
Stock Analyst at Roth Capital
(2.43)
# 2,370
Out of 5,174 analysts
16
Total ratings
57.14%
Success rate
11.27%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Adam Walsh
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EQ Equillium | Initiates: Buy | $12 | $1.95 | +515.38% | 1 | Mar 13, 2026 | |
| APLS Apellis Pharmaceuticals | Initiates: Buy | $31 | $17.23 | +79.92% | 1 | Mar 13, 2026 | |
| INSM Insmed | Initiates: Buy | $212 | $139.14 | +52.36% | 1 | Jan 23, 2026 | |
| VTVT vTv Therapeutics | Initiates: Buy | $58 | $36.21 | +60.18% | 1 | Jan 23, 2026 | |
| ASND Ascendis Pharma | Maintains: Buy | $146 → $171 | $215.54 | -20.66% | 3 | Apr 20, 2020 | |
| GLPG Galapagos NV | Maintains: Buy | $121 → $188 | $29.80 | +530.87% | 4 | Jul 15, 2019 | |
| CORT Corcept Therapeutics | Downgrades: Hold | n/a | $33.82 | - | 4 | May 31, 2018 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $74 → $77 | $18.50 | +316.22% | 1 | Apr 18, 2018 |
Equillium
Mar 13, 2026
Initiates: Buy
Price Target: $12
Current: $1.95
Upside: +515.38%
Apellis Pharmaceuticals
Mar 13, 2026
Initiates: Buy
Price Target: $31
Current: $17.23
Upside: +79.92%
Insmed
Jan 23, 2026
Initiates: Buy
Price Target: $212
Current: $139.14
Upside: +52.36%
vTv Therapeutics
Jan 23, 2026
Initiates: Buy
Price Target: $58
Current: $36.21
Upside: +60.18%
Ascendis Pharma
Apr 20, 2020
Maintains: Buy
Price Target: $146 → $171
Current: $215.54
Upside: -20.66%
Galapagos NV
Jul 15, 2019
Maintains: Buy
Price Target: $121 → $188
Current: $29.80
Upside: +530.87%
Corcept Therapeutics
May 31, 2018
Downgrades: Hold
Price Target: n/a
Current: $33.82
Upside: -
Ultragenyx Pharmaceutical
Apr 18, 2018
Maintains: Buy
Price Target: $74 → $77
Current: $18.50
Upside: +316.22%